By Alicia Wallace The DEA is expected to finalize on Wednesday the previously suggested Schedule II status for Syndros, the FDA-approved drug developed by Insys Therapeutics.

Read this full story…..: DEA finalizing Schedule II status for synthetic THC drug Syndros